REVIVA PHARMACEUTICALS HOLDI (RVPH)
US76152G1004 - Common Stock
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial...
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva to Participate in the UBS Global Healthcare Conference
CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference
CUPERTINO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom...
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024
RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reviva Pharmaceuticals (NASDAQ:RVPH) just reported results for the second quart...
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights
– Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Registrational RECOVER-2 trial in schizophrenia expected to initiate Q3...
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:...
Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:...
Reviva to Participate in the BIO International Convention
CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:...
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024
RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
RVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:...
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
RVPH stock results show that Reviva Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reviva Pharmaceuticals (NASDAQ:RVPH) just reported results for the fourth quart...
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have...
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia –
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Reviva to Present at the UBS Virtual CNS Day
CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...